Page 34
RT is cheaper than chemotherapy and immunotherapy
The number of RT centres in Europe is increasing , however is still less than that of the US
RT offers a cheaper alternative to chemotherapy or late-stage immunotherapy The average cost of cancer surgery in the US ranges from $ 14,161 ( robot assisted ) for a prostatectomy to $ 56,587 for a pancreatectomy . The average costs of chemotherapy ( includes both modern combined with standard chemo in most cases ) is c .$ 102,395 / year . Biologics treatment such as ICI regimens are even more costly . Following on from Table 18 , the more important and crucial question is the extent to which particle therapy can penetrate the RT market .
To meet demand , increases in the number and utilisation of RT systems are required The increasing cost of drug therapies and inappropriate use of late-stage treatments are a serious challenge . RT is growing in importance , driven by improving precision to treat tumours by minimising the toxicity to the tumour-surrounding tissue . While the US has already embraced the use of RT with a utilisation rate of > 50 % for the treatment of diagnosed cancers , Europe and other regions have significantly lower adoption rates . The industry is likely to benefit from regions catching up with ASTRO and ESTRO recommendations ( between 40 % and 55 %). The RT capacity in Europe varies , however since our previous COMPASS Research Report ( 7 th Oct 2019 entitled “ Cancer – Strategy for affordable care ), the variation has decreased significantly . The average number of RT machines per million of population is 5.5 , 4.5 , and 4.2 in Bulgaria , Poland , and Romania , with more developed countries remaining higher with this figure being 9.4 , 9.6 , and 8.4 for Denmark , France , and The Netherlands . In the former group , there is still unmet RT need with a requirement to further modernise capital infrastructure . Trends in PT adoption follow a similar pattern , with patients in many countries still unable to access these resources despite great need for it . Ultimately , ease of implementation is the biggest challenge to overcome to allow patients access to such treatments .
Figure
29 : Number of RT centres per million in select EU states
Source : goetzpartners Research , DIRAC
Figure 30 : PT drivers
Source : goetzpartners Research
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .